Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolutegravir use in children aged 6 to 12 years with HIV in Brazil
RBR-87x8h69Recruiting
- Sponsor
- Universidade Federal de Minas Gerais
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of dolutegravir in human immunodeficiency virus infection (HIV), sponsored by Universidade Federal de Minas Gerais. Primary endpoints: Virologic failure, CD4+ cell count change and 1 more. Started Oct 2021; status: recruiting.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on RBR-87x8h69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-87x8h69.